

HOUSE OF REPRESENTATIVES  
THE TWENTY-NINTH LEGISLATURE  
REGULAR SESSION OF 2017

RECEIVED

2017 MAR 14 A 8:24

COMMITTEE ON HEALTH

Rep. Della Au Belatti, Chair  
Rep. Bertrand Kobayashi, Vice Chair

SERGEANT-AT-ARMS  
HOUSE OF  
REPRESENTATIVES

Rep. Sharon E. Har      Rep. Chris Todd  
Rep. Dee Morikawa      Rep. Andria P.L. Tupola  
Rep. Marcus R. Oshiro

NOTICE OF HEARING

DATE: Thursday, March 16, 2017  
TIME: 8:30 AM  
PLACE: Conference Room 329  
State Capitol  
415 South Beretania Street

A G E N D A

SB 503, SD2  
(SSCR754)  
Status

RELATING TO VICTIMS OF SEXUAL VIOLENCE.  
Requires health insurance coverage for case management services by qualified mental health providers for victims of sexual violence and abuse. Takes effect on 6/1/2050. (SD2)

HLT, CPC, FIN

SB 505, SD1  
(SSCR565)  
Status

RELATING TO HEALTH.  
Requires an opioid therapy informed consent process agreement to be executed between a patient and any prescriber of opioids within the State under certain conditions. Requires the harm reduction services branch of the department of health to develop and make available a template of an opioid therapy informed consent process agreement for use in the State. Specifies the contents of the template. Requires all opioid therapy informed consent process agreements to be filed with the harm reduction services branch of the department of health for monitoring. Establishes that prescribers who violate the mandatory opioid therapy informed consent process shall be subject to disciplinary action established by the Hawaii Medical Board or the State Board of Nursing. Requires all prescribers who are authorized to prescribe opioids to register with Hawaii's electronic prescription accountability system. Limits initial prescriptions for opioids and benzodiazepines to a maximum of seven consecutive days with certain exceptions. Effective 7/1/2050. (SD1)

HLT, CPC

SB 514, SD1  
(SSCR556)  
Status

RELATING TO HEALTH.  
Authorizes pharmacists to administer the human papillomavirus, Tdap (tetanus, diphtheria, pertussis), meningococcal, or influenza vaccine to persons between eleven and seventeen years of age. Specifies requirements pharmacists must meet prior to administering the human papillomavirus, Tdap (tetanus, diphtheria, pertussis), meningococcal, or influenza vaccine. (SD1)

HLT, CPC



SB 513, SD1  
(SSCR555)  
Status

RELATING TO CONTRACEPTIVE SUPPLIES.  
Authorizes pharmacists to prescribe and dispense self-administered hormonal contraceptive supplies to patients, regardless of a previous prescription from an authorized prescriber. Specifies requirements pharmacists must meet prior to prescribing and dispensing contraceptive supplies. Enables pharmacists to be reimbursed for prescribing and dispensing contraceptive supplies. (SD1)

HLT, CPC

SB 384, SD2  
(SSCR866)  
Status

RELATING TO PRESCRIPTIVE AUTHORITY FOR CERTAIN CLINICAL PSYCHOLOGISTS.  
Authorizes and establishes procedures and criteria for prescriptive authority for clinical psychologists who meet specific education, training, and registration requirements, including requiring prescribing psychologists to adhere to all applicable statutory regulations. Requires the board of psychology to report to the legislature prior to the regular session of 2021. Takes effect on January 7, 2019. Sunsets August 31, 2025. (SD2)

HLT, FIN

SB 997, SD1  
(SSCR892)  
Status

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.  
Updates the Uniform Controlled Substances Act to make it consistent with amendments in federal controlled substances law as required under the authority to schedule controlled substances. Takes effect on 1/7/2019. (SD1)

HLT, JUD

SB 1312, SD2  
(SSCR813)  
Status

RELATING TO THE LICENSURE OF MIDWIVES.  
Establishes the board of midwifery to regulate the practice of midwifery by certified midwives and certified professional midwives. Requires licensing of certified midwives and certified professional midwives to commence beginning on July 1, 2020. Requires the department of commerce and consumer affairs to convene a working group of interested stakeholders and submit a report to the legislature. Effective July 1, 2020. (SD2)

HLT, CPC, FIN

#### DECISION MAKING TO FOLLOW

Persons wishing to offer comments should submit testimony at least 24 hours prior to the hearing. Testimony should indicate:

- Testifier's name with position/title and organization;
- The Committee(s) to which the comments are directed;
- The date and time of the hearing; and
- Measure number.

While every effort will be made to incorporate all testimony received, materials received on the day of the hearing or improperly identified or directed, may be distributed to the Committee after the hearing.

Submit testimony in ONE of the following ways:

PAPER: 15 copies (including an original) to Room 403 in the State Capitol;

FAX: For testimony less than 5 pages in length, transmit to 808-586-6311 (Oahu) or 1-800-535-3859 (for Neighbor Islander without a computer to submit testimony through e-mail or the Web); or

WEB: For testimony less than 10MB in size, transmit from <http://www.capitol.hawaii.gov/submittestimony.aspx>.

Testimony submitted will be placed on the legislative website. This public posting of testimony on the website should be considered when including personal information in your testimony.

Hearing HLT 03-16-17

